Preclinical Safety
Compound profiling is critical during the preclinical evaluation of drug candidates. Issues with metabolism and pharmacodynamics are the primary reasons for compound failure in clinical trials.
Fundacion MEDINA addresses preclinical issues by identifying potential liabilities of new leads in the early stages of the drug-discovery process:
- Drug Metabolism
- Cardiotoxicity (Ion channel inhibition)
- Cell toxicity
- Mitochondrial toxicity
- Genotoxicity
- Neurotoxicity
Drug Metabolism
- Solubility
- Human CYP450 Inhibition & Induction
- Microsomal Stability and profiling
- Plasma protein binding
Cardiotoxicity (Ion channel inhibition)
- hERG
- Nav1.5
- Cav1.2
Cell toxicity
Mitochondrial toxicity
- Mitochondrial Membrane Potential
- ROS
- Superoxides
- Mitochondrial Calcium
- ATP/AMP/ADP levels
- NADH concentration
- Oxygen consumption
Genotoxicity
- AMES TEST (Mini-Ames MPF 98/100)
Neurotoxicity
- Neurotransmitter Receptors
MEDINA's facilities and services are state-of-the-art, and fast turn-around times are guaranteed by the screening platform’s high degree of automation.
MEDINA provides an advantage with its extensive experience garnered by its scientists at the MSD, Spain facilities, formerly the MRL Reference Center for drug safety.
MEDINA and Neuron BPh have reached an agreement to jointly publicize their technologies and pre-clinical integrated platform for the pharmaceutical industry.
 |
 |
 |